Disinfectant Use in Uncertain Times: A Survival Roadmap

Author: Marc-Oliver Wright, MT(ASCP), MS, CIC, FAPIC

Categories: General Infection Prevention September 15, 2020
Hospital Storage Closet_supplies September 15, 2020

The pandemic of SARS-CoV-2 has upended healthcare delivery in unprecedented ways. Availability of essential medical supplies have come up short as a result of increased demand, manufacturing delays, international trade/shipping delays and lack or shortages of raw materials.

This is especially true of personal protective equipment (PPE) such as medical respirators, but hospital-grade disinfectants are not immune from these concerns.1 Disinfectants are further complicated by the newness of the virus, necessitating EPA’s recommended List N: Disinfectants for Use Against SARS-CoV-2, which in turn leads to increased demand for select disinfectant products. 2

As of this writing (September 2020) there is little evidence to suggest that these concerns are easing. The Centers for Disease Control and Prevention (CDC) has addressed supply chain related issues for the SARS-CoV-2 pandemic for PPE but has not offered similar guidance specific to disinfectant supply disruptions. These guidelines describe scenarios for contingency and crisis capacity.3 Uncertain times warrant proactive, creative planning and navigating the presumably turbulent future will necessitate a combination of tracking, conservation and mitigation. This document seeks to address each of these three areas though it is not feasible to comprehensively address all potential scenarios.

Tracking

In order to mitigate supply shortages, it is essential that facilities know, understand and continuously track stock. Often, supply chain management may have existing resources to assist. However, if this is not the case, there is an alternate option.

In April 2020, National Institute for Occupational Safety and Health (NIOSH) and the CDC released a no-cost PPE Burn Rate Calculator application for desktop and mobile devices on Apple® and Android platforms. Despite the name and default settings, the user can create additional categories beyond gown, gloves and respirators (e.g. List N disinfectant wipe, List N disinfectant spray, non-List N disinfectant wipe) in order to similarly track and trend utilization by patient volume. After only two days of data points, the program can estimate when the supply of disinfectant(s) will run out and continues to update as additional data points (days) are entered. Users can use this information to optimize ordering as well as determine whether conservation efforts are successfully impactful (burn rate goes down).CLICK HERE to see a sample.

Conservation

Conserving disinfectants can be achieved through several strategies. Dedicating otherwise non-dedicated patient care equipment (assist devices, glucometers, wireless tablets) to suspected or confirmed COVID-19 case patient rooms reduces the need to disinfect between each use to patient discharge/transfer.

If an organization’s supply includes List N and non-List N disinfectants, allocate the List N products according to need.  While confirmed or suspected COVID-19 cases are the obvious highest risk/need, intake/assessment areas such as Urgent Care Clinics and Emergency Departments should also be considered high risk, while elective procedure areas with pre-admission screening/testing and case delay of suspect or known positives may be considered lower risk. Ideally, each patient care area should be assessed for risk and List N disinfectants allocated according to need and product availability in the context of area specific utilization/burn rate.

Some applicators may be more conservative in their product utilization than others. For example, a pour-based disinfectant may use more product for a task than if the same product was applied to a plain disposable towelette applicator or spray bottle – although doing so violates manufacturer’s instructions for use-thus warranting a risk assessment and applicator labelling/employee education. Importantly, the EPA specifically advises against this activity as using the product in a manner inconsistent with its labeling is a violation of federal law. 4 Overall it is important to consider products that will sustain a longer use case and adhere to manufacturing guidelines (or instructions for use).

Mitigation

Conservation may not be enough to afford sufficient quantities of surface disinfectants. Mitigation strategies can range from inconvenient to high risk from a safety and/or regulatory perspective.

Facilities may seek out or be offered alternative products than they customarily utilize. Product conversions can be challenging under ideal conditions-yet alone during a pandemic. Facilities undergoing such conversion(s) should make certain that their employees are well informed of the following:

  • List-N status or appropriateness of use with suspected or confirmed COVID-19 cases
  • Contact/Wet/Kill time(s)
  • Specific compatibility or safe handling instructions

If the facility is unable to secure any List-N disinfectants and they screen or treat confirmed or suspect COVID-19 patients, facilities should communicate with local and/or state public health agencies who may be able to assist in procurement.

Author

Marc-Oliver Wright MT(ASCP), MS, CIC, FAPIC
Marc-Oliver Wright, PDI Clinical Science Liaison Clinical Science Liaison, PDI

Profile

Marc wanted to be an epidemiologist as a teenager and was first introduced to infection prevention when he performed DNA fingerprinting of multidrug resistant organisms for research activities, surveillance and outbreak investigations while in graduate school. He became an infection preventionist, a research epidemiologist and ultimately a corporate director of infection prevention and quality for a multi-hospital system. Marc served APIC at the local and national level, has published over 50 articles and served on the editorial board of the American Journal of Infection Control for a decade.

Marc now serves as PDI’s Clinical Science Liaison (CSL), for the Central Region-14 states across the Midwest.

Contact

Phone: 608-886-4325

Company Website:Pdihc.com

Email: Marc-oliver.wright@pdihc.com

Hobbies

Cooking
Collecting vinyl albums

Education

University of Illinois – Chicago
Master of Science: Public Health Sciences: Epidemiology
Bachelor of Science: Clinical Laboratory Sciences

Certification
American Society for Clinical Pathology (ASCP)- MT (ASCP)
Certification Board of Infection Control (CBIC)- CIC

Fellowship
Association for Professionals in Infection Control and Epidemiology, Inc-FAPIC

Why I love what I do

I believe that infection prevention is 5% knowing what to do and 95% figuring out how to get it done. The role of the CSL at PDI is a combination of knowing the science, teaching it to others and helping them through the implementation process. There is something truly rewarding in helping multiple healthcare organizations achieve their goals of safer, better patient care.

Areas of Expertise

Informatics
Human factors
Surveillance methodology
Multi-drug resistant organisms
Healthcare systems
Leadership

More about Marc-Oliver Wright Less about Marc-Oliver Wright